Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis-Reference-Cited by-同舟云学术

Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis

Published:2020-04 Issue:2 Volume:3 Page:176-182
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Rescigno Pasquale,Dolling David,Conteduca Vincenza,Rediti Mattia,Bianchini Diletta,Lolli Cristian,Ong Michael,Li Haoran,Omlin Aurelius G.,Schmid Sabine,Caffo Orazio,Zivi Andrea,Pezaro Carmel J.,Morley Courtney,Olmos David,Romero-Laorden Nuria,Castro Elena,Saez Maria I.,Mehra Niven,Smeenk Stella,Sideris Spyridon,Gil Thyerry,Banks Patricia,Sandhu Shaneen K.,Sternberg Cora N.,De Giorgi Ugo,De Bono Johann S.

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference18 articles.

1. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate Specific Antigen;Bubley;J Clin Oncol,1999

2. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer;Kelly;J Clin Oncol,1993

3. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials 3;Scher;J Clin Oncol,2016

4. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone refractory prostate cancer to suramin therapy;Sridhara;J Clin Oncol,1995

5. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916;Hussain;J Clin Oncol,2009

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Early PSA Response After Abiraterone Treatment for Metastatic Castration Resistant Prostate Cancer;2024-06-12

2. Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer;Clinical Cancer Research;2023-03-30

3. Identification and Validation of FGF-Related Prognostic Signatures in Prostate Cancer;Disease Markers;2023-02-21

4. Prostate-specific Antigen Kinetics During Androgen-deprivation Therapy Predict Response to Enzalutamide in Metastatic Castration-resistant Prostate Cancer;Anticancer Research;2022-12-30

5. FCGR3A: A new biomarker with potential prognostic value for prostate cancer;Frontiers in Oncology;2022-11-24